NYSE · WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES · LARGE CAP
Herbalife Ltd. HLF
18 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$5.0B
▲ 0.9% vs FY2024
EPS · FY25
$2.20
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
4.5%
Dividend coverage
11.3×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 5.0B
Revenue, FY2025 · full 18-year series below
Revenue
Net income
5 cents of every revenue dollar became profit this year.
Per share
USD 2.20
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 11.3 times — the rest stayed in the company.
Profitability
—
Return on equity, FY2025
ROE
Operating margin9.5%
Net margin4.5%
Return on assets8.3%
Returned to shareholders
USD 8.2M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 8.2M
Share of profit3.6%
Consecutive raises—
USD 8.2M in buybacks — 4% of the year's profit went back to shareholders.
Growth
−1.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−1.1%
−1.9%
+1.2%
+4.2%
Net income
−10.8%
−9.3%
−3.9%
−1.6%
EPS, diluted
−12.0%
−4.5%
Dividend / share
−25.7%
−5.6%
Returned to shareholders
−61.8%
−61.1%
−6.8%
−19.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.10B
Shares outstanding, FY2025
Change, 5 years−14.0%
Change, 10 years—
The share count shrank 14% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 2.8B
total assets, end of FY2025
Total assetsUSD 2.8B
EquityUSD -515.1M
CashUSD 353.1M
Gross debtUSD 2.0B
Net debtUSD 1.6B
Current ratio1.13×
Net debt stands at -318% of equity.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Revenue $B
5.0
5.0
5.1
5.2
5.8
5.5
4.9
4.9
4.4
4.5
4.5
5.0
4.8
4.1
3.5
2.7
2.3
2.4
Operating income $B
0.5
0.4
0.4
0.5
0.7
0.6
0.6
0.7
0.6
0.5
0.6
0.5
0.7
0.7
0.6
0.4
0.3
0.3
EBITDA $B
0.6
0.5
0.4
0.6
0.8
0.7
0.6
0.8
0.7
0.5
0.7
0.6
0.8
0.7
0.6
0.5
·
·
Income tax $B
0.0
−0.1
0.1
0.1
0.1
0.1
0.1
0.2
0.3
0.1
0.1
0.1
0.2
0.2
0.1
0.1
0.1
0.1
Net income $B
0.2
0.3
0.1
0.3
0.4
0.4
0.3
0.3
0.2
0.3
0.3
0.3
0.5
0.5
0.4
0.3
0.2
0.2
EPS, diluted $
2.20
2.50
1.42
3.23
4.13
2.77
2.20
1.98
1.29
1.51
3.97
3.40
4.91
3.94
3.32
2.32
1.61
3.36
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
0.30
1.20
1.20
0.73
0.45
0.40
0.80
Payout %
·
·
·
·
·
·
·
0
0
0
0
10
23
29
21
18
24
23
ROE %
·
·
·
·
·
·
·
·
·
364.1
·
284.5
111.4
98.3
81.2
71.0
68.6
91.5
Shares out B
0.10
0.10
0.10
0.10
0.10
0.12
0.14
0.14
0.16
0.19
0.09
0.09
0.10
0.11
0.12
0.12
0.12
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
70 of 70
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed